Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study.

Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K; ASCITES Clinical Pharmacology Group.

J Int Med Res. 2012;40(6):2381-93. Erratum in: J Int Med Res. 2013 Jun;41(3):915.

PMID:
23321196
2.

Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.

Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K; ASCITES 14-Day Administration Study Group.

J Int Med Res. 2013 Jun;41(3):835-47. doi: 10.1177/0300060513480089. Epub 2013 May 17.

PMID:
23685892
3.

Tolvaptan for the treatment of liver cirrhosis oedema.

Sakaida I.

Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):461-70. doi: 10.1586/17474124.2014.903797. Epub 2014 Mar 29. Review.

PMID:
24678622
4.

Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).

Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S33-45. doi: 10.1007/s10557-011-6304-x.

PMID:
22120092
5.

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.

Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N.

PLoS One. 2017 Mar 31;12(3):e0174649. doi: 10.1371/journal.pone.0174649. eCollection 2017.

6.

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.

Sakaida I, Nakajima K, Okita K, Hori M, Izumi T, Sakurai M, Shibasaki Y, Tachikawa S, Tsubouchi H, Oka H, Kobayashi H.

J Gastroenterol. 2015 Oct;50(10):1047-53. doi: 10.1007/s00535-015-1052-5. Epub 2015 Feb 18.

7.

Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.

Fukunami M, Matsuzaki M, Hori M, Izumi T; Tolvaptan Investigators.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S47-56. doi: 10.1007/s10557-011-6348-y.

PMID:
22120093
8.

Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T; Tolvaptan Investigators.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S19-31. doi: 10.1007/s10557-011-6303-y.

PMID:
22120091
9.

Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.

Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S5-17. doi: 10.1007/s10557-011-6299-3.

PMID:
22120090
10.

Phase III clinical pharmacology study of tolvaptan.

Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A; Tolvaptan Investigators.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S57-65. doi: 10.1007/s10557-011-6349-x.

PMID:
22120094
11.

Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.

Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.

Dig Dis. 2016;34(6):659-664. Epub 2016 Oct 17.

PMID:
27750234
12.

Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.

Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.

World J Gastroenterol. 2014 Aug 28;20(32):11400-5. doi: 10.3748/wjg.v20.i32.11400.

13.

Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.

Goto A, Terai S, Nakamura M, Matsumoto M, Sakaida I.

Clin J Gastroenterol. 2015 Feb;8(1):47-51. doi: 10.1007/s12328-014-0545-8. Epub 2014 Dec 5.

14.

Cases with Refractory Ascites and a Delayed Response to Tolvaptan.

Hagiwara S, Nishida N, Chishina H, Ida H, Sakurai T, Komeda Y, Kitano M, Kudo M.

Intern Med. 2016;55(22):3273-3277. Epub 2016 Nov 15.

15.

Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.

Kida K, Shibagaki Y, Tominaga N, Matsumoto N, Akashi YJ, Miyake F, Kimura K.

Clin Pharmacokinet. 2015 Mar;54(3):273-84. doi: 10.1007/s40262-014-0194-6.

PMID:
25305049
16.

Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.

Yamada T, Ohki T, Hayata Y, Karasawa Y, Kawamura S, Ito D, Kojima K, Seki M, Toda N, Tagawa K.

Clin Drug Investig. 2016 Oct;36(10):829-35. doi: 10.1007/s40261-016-0434-7.

PMID:
27405984
17.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

JAMA. 2004 Apr 28;291(16):1963-71.

PMID:
15113814
18.

Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial.

Okita K, Kawazoe S, Hasebe C, Kajimura K, Kaneko A, Okada M, Sakaida I; ASCITES Dose-Finding Trial Group.

Hepatol Res. 2014 Jan;44(1):83-91. doi: 10.1111/hepr.12099. Epub 2013 Mar 27.

PMID:
23530991
19.

Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.

Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y.

Nephron. 2015;130(1):8-12. doi: 10.1159/000381859. Epub 2015 Apr 30.

PMID:
25926290
20.

[Effect of tolvaptan on ascites due to malignancy].

Mitsuhashi N, Nemoto S, Satoh Y, Aoki Y, Teranaka R, Sasaki K, Shimazaki R, Ueda A, Nishino H, Akiyama T, Hosokawa I, Yoichi T, Kawamoto J, Kuboki S, Yoshitomi H, Kato A, Shimizu Y, Ohtsuka M, Shimizu H, Miyazaki M.

Gan To Kagaku Ryoho. 2015 Feb;42(2):201-5. Japanese.

PMID:
25743139

Supplemental Content

Support Center